Neil Woodford’s Latest Buys: Centrica PLC, Babcock International Group PLC, Paypoint plc, Drax Group Plc, Benchmark Holdings PLC And Midatech Pharma PLC

Catching the eye among the ace investor’s latest trades are Centrica PLC (LON:CNA), Babcock International Group PLC (LON:BAB), Paypoint plc (LON:PAY), Drax Group Plc (LON:DRX), Benchmark Holdings PLC (LON:BMK) and Midatech Pharma PLC (LON:MTPH).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Neil Woodford continues to build and shape the CF Woodford Equity Income fund he launched last June after calling time on his 26-year career with Invesco Perpetual.

During December, the master investor put more money into existing holdings Centrica (LSE: CNA), Babcock International (LSE: BAB), Paypoint (LSE: PAY), Drax (LSE: DRX) and Benchmark (LSE: BMK), and took a new position in Midatech Pharma.

British Gas owner Centrica and engineering support services group Babcock are two of Woodford’s less visible FTSE 100 holdings.

Centrica’s shares are trading at multi-year lows, with investor sentiment hit by everything from unfavourable weather patterns during 2014 to political posturing and regulatory uncertainty surrounding the UK’s big energy firms. As a result, Centrica trades on a modest 12-month forecast P/E of 13, with a massive 6.4% dividend yield.

Babcock is also out-of-favour with the market. Its shares are at 52-week lows. Babcock doesn’t have much of a dividend yield and its P/E of 13.3 is a little higher than Centrica’s. But Woodford and his team consider both companies to be at “attractive valuation levels”.

The same goes for FTSE 250 firm Paypoint. This company, which is the UK’s leading consumer payments processor, through its retail networks, and internet and mobile channels, trades on a slightly growthier P/E of 14, but is a slightly growthier firm.

Fellow FTSE 250 constituent Drax is another holding that Woodford added to in December. The electricity generator’s shares took a bit of a dive on a surprise announcement from the Department of Energy & Climate Change that it would be consulting on biomass policy changes.

Woodford and his team acknowledge that the business is exposed to “considerable political risk currently”, but said: “Drax remains a strategically important asset in the UK electricity sector and we are confident in its ability to generate attractive returns for shareholders in the future”.

Woodford is best known for his big blue-chip holdings, but he has within the fund what might be called a sub-portfolio of dynamic smaller cap companies in the technology and medical sectors.

Woodford added to his holding in one of the larger of these companies: £270m animal healthcare technology firm Benchmark. He was happy to pay 85p a share when Benchmark did a placing to raise funds to acquire salmon breeding and genetics companies SalmoBreed and Stofnfiskur.

Finally, Woodford also participated in a 267p-a-share IPO of Midatech Pharma, a company which uses tiny particles of pure gold to treat cancer and other medical conditions. Woodford stumped enough cash to give him 20% of the £74m AIM-listed firm’s shares.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

G A Chester has no position in any shares mentioned. The Motley Fool UK has recommended Centrica. The Motley Fool UK owns shares of PayPoint. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Photo of a man going through financial problems
Investing Articles

Is a stock market crash coming? And what should I do now?

Global investors are panicking about a new US stock market crash in the days or weeks ahead. Here's how I'm…

Read more »

Investing Articles

FTSE shares: a brilliant opportunity for investors to get rich?

With valuations in the US looking full, Paul Summers thinks there's a good chance that FTSE stocks might become more…

Read more »

Growth Shares

2 FTSE 100 stocks that could outperform the index in 2025

Jon Smith flags up a couple of FTSE 100 stocks that have strong momentum right now and have beaten the…

Read more »

Happy young female stock-picker in a cafe
Investing Articles

1 stock market mistake to avoid in 2025

This Fool has been battling bouts of of FOMO recently, as one of his growth shares enjoys a big bull…

Read more »

Investing Articles

2 no-brainer buys for my Stocks and Shares ISA in 2025

Harvey Jones picks out a couple of thriving FTSE 100 companies that he's keen to add to his Stocks and…

Read more »

Number three written on white chat bubble on blue background
Investing For Beginners

3 investing mistakes to avoid when buying UK shares for 2025

Jon Smith flags up several points for investors to note when it comes to thinking about which UK shares to…

Read more »

Investing Articles

Will the rocketing Scottish Mortgage share price crash back to earth in 2025?

The recent surge in the Scottish Mortgage share price caught Harvey Jones by surprise. He was on the brink of…

Read more »

Investing Articles

2 cheap shares I’ll consider buying for my ISA in 2025

Harvey Jones will be on the hunt for cheap shares for his ISA in 2025 and these two unsung FTSE…

Read more »